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Background: Individualized Medicine aims at providing optimal treatment for an individual patient at a given time
based on his specific genetic and molecular characteristics. This requires excellent clinical stratification of patients as
well as the availability of genomic data and biomarkers as prerequisites for the development of novel diagnostic
tools and therapeutic strategies. The University Medicine Greifswald, Germany, has launched the “Greifswald
Approach to Individualized Medicine” (GANI_MED) project to address major challenges of Individualized Medicine.
Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of
findings relevant to Individualized Medicine into clinical practice.
Methods/design: Clinical patient cohorts (N > 5,000) with an emphasis on metabolic and cardiovascular diseases
are being established following a standardized protocol for the assessment of medical history, laboratory
biomarkers, and the collection of various biosamples for bio-banking purposes. A multi-omics based biomarker
assessment including genome-wide genotyping, transcriptome, metabolome, and proteome analyses complements
the multi-level approach of GANI_MED. Comparisons with the general background population as characterized by our
Study of Health in Pomerania (SHIP) are performed. A central data management structure has been implemented to
capture and integrate all relevant clinical data for research purposes. Ethical research projects on informed consent
procedures, reporting of incidental findings, and economic evaluations were launched in parallel.
Keywords: Personalized Medicine, Individualized Medicine, Epidemiology* Correspondence: grabeh@uni-greifswald.de
1Department of Psychiatry and Psychotherapy, University Medicine
Greifswald, Ellernholzstraße 1-2, Greifswald 17475, Germany
Full list of author information is available at the end of the article
© 2014 Grabe et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Grabe et al. Journal of Translational Medicine 2014, 12:144 Page 3 of 15
http://www.translational-medicine.com/content/12/1/144Background
An increase in individualized diagnostic and therapeutic
strategies is considered as means to improve patients’
treatment efficacy and safety. It might also allow for
better individual outcome prediction and risk assess-
ment. Moreover, individualized prevention and early
intervention strategies are conceivable. On the eco-
nomic side, a more efficient allocation of resources is
pursued. Recently developed high throughput OMICs
technologies are thought to enable more targeted diag-
nostic and treatment approaches. However, the issue
of Individualized Medicine remains controversial. A
lack of solid scientific evidence for the clinical utility
of nearly all novel biomarkers is raised amongst the
most common criticisms [1]. Furthermore, potential
societal and ethical consequences of Individualized Medi-
cine are sometimes not adequately addressed or even
considered.
The research project “Greifswald Approach to Individ-
ualized Medicine” (GANI_MED) aims at implementing
an increasing number of individualized diagnostic and
therapeutic strategies in a university hospital and has its
focus on cardiovascular, cerebrovascular and metabolic
diseases and on ethical as well as economic aspects of
Individualized Medicine. The main objectives are as
follows:
 To recruit patient cohorts and to thoroughly
examine these cohorts with standardized clinical
measures
 To create a centralized bank of biologic specimens
to support research needs and clinical care
 To link genetic and molecular analyses (‘omics’) to
clinical data
 To assist investigators and encourage collaboration
across different medical specialties.
To address these objectives a novel hospital infor-
mation system extension that allows the efficient re-
trieval of routine clinical data for research purposes
was necessary. At the same time, a large scale re-
search database storing all data obtained in the hos-
pital while fully conforming to high data safety standards
needed to be established. Further, the potential ethical and




GANI_MED is conceptualized as cohort study with in-
dividual follow-ups. Starting with six main cohorts in-
cluding patients with common diseases, three additional
cohorts joined during the recruitment period. All subjects
were regular patients of the university hospital exceptsome of the patients with chronic renal failure who were
also recruited from special treatment centers for dialysis.
Study nurses or physicians from the participating depart-
ments enrolled the patients. All cohorts are thoroughly
phenotyped using clinical methods, imaging technologies
(ultrasonography, magnetic resonance imaging (MRI)),
and OMICS approaches (Table 1). GANI_MED was ap-
proved by the ethics committee of the Medical Faculty of
the Ernst-Moritz-Arndt University Greifswald. After
complete description of the study to the patients, written
informed consent is obtained. New infrastructures have
been implemented (e.g. automated biobank, medical in-
formatics) and additional research groups (e.g. research
on ethical challenges) were founded. In the future, we plan
to integrate all patients of the university hospital into the
research data base, at a lower level of data assessment as
compared to the present assessments in GANI_MED.
Study population
We are recruiting six main cohorts with common cardio-
vascular, cerebrovascular or metabolic conditions: heart
failure (expected n = 1200), stroke (expected n = 600),
periodontal disease (expected n = 800), renal insuffi-
ciency (expected n = 400), metabolic syndrome (expected
n = 1600), and fatty liver disease (expected n = 400). The
official start of the patient recruitment was July 7, 2011.
Three further cohorts (patients with sepsis, pulmonary
diseases, and adverse medication effects) have been
launched in the meantime (for detailed description of
the cohorts see below).
Study procedures
Standardized assessments and examinations
One of the key elements of GANI_MED is extensive
quality control and standardization in the data acquisi-
tion. This is especially challenging as the data acquisi-
tion is part of routine care for patients, who are admitted
to the university hospital Greifswald. Therefore, we have
implemented an extended array of quality control mea-
sures regarding clinical phenotyping of our GANI_MED
patients. These include computer-assisted standardized
interviews to obtain the medical history (Table 2) and the
medication taken by the patient. Standard operating
procedures have been defined for each clinical examin-
ation, including the measurements of blood pressure,
height, weight, hip circumference, waist circumference,
and different ultrasonographic measures of the carotid
arteries, kidney, liver, pancreas, and uterus. In contrast
to established procedures in clinical practice, the med-
ical staff has not only been trained for performing exami-
nations, but also certified according to SHIP standards [2].
Numerous questionnaires are used to further assess the
patients´ individual characteristics (Table 3). For example,
in all GANI_MED cohorts childhood traumata (CTS, [3])






















Clinical examination × × × × × × × ×
Somatometric measures × × × × × × × ×
Blood pressure × × × × × × × ×
Number of teeth × × × × × × × ×
ECG × × - - × - - -
Echocardiography × (×) - - × - - -
Echocardiography, diastolic
function
× - - - × - - -
Ankle-Brachial-Index (×) - - - (×) - - -
Pulse-wave-analysis (×) - - - (×) - - -
Endothelial function (×) - - - (×) - - -
Cardiopulmonary exercise (×) - - - (×) - - -
Carotid ultrasonography - × × - - - - -
Oral examinations - × × - - - - -
MRI of the head - × × - - × - -
Renal ultrasound - - - × - - - -
Bioelectrical impedance
analysis
- - - × - - - ×
OGTT - - - - × × × -
Gynecological examinations - - - - - - × -
Uterus ultrasound - - - - - - × -
Liver ultrasound - - - - - - - ×
Liver elastography - - - - - - - ×
Pancreas ultrasound - - - - - - - ×
Liver biopsy - - - - - - - ×
MRI of the liver - - - - - - - ×
*Polycystic Ovary Syndrome.
x = available, (x) = available only in subgroups, − = not available.
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sured to enable an integrative approach to the impact of
early traumatization and depression on the course and
treatment response in somatically ill patients.
Moreover, data collection is constantly monitored for
comprehensiveness, as well as for examiner variation
and time trends due to unrequested methodical modi-
fication. Automated monitoring systems allow online
recruitment monitoring and weekly feedbacks to the
examiners.
By implementing these quality control measures we
expect to obtain data that are of higher quality than is
usually achieved in clinical contexts. The high data qual-
ity will not only allow us to use these data for scientific
purposes in GANI_MED, but may also be beneficial for
clinical practice.Standardized medical history
The medical history, as it is obtained in clinical routine,
is highly variable in terms of the information collected.
In routine care, information collection varies with the
qualification and time allocation of the examiner, the set-
ting, the symptoms presented by the patients, the wording
of questions, the sequence of questions, and the recording
of answers. Each of these factors may affect the validity of
the data, thereby limiting their exploitability for scientific
purposes. Furthermore, the anamnesis is still often docu-
mented on paper rather than electronically, which further
complicates its systematic re-use.
In order to standardize the medical history across the
GANI_MED cohorts, we have developed a basic set of
obligatory, standardized questions (Table 2), extended by
optional cohort-specific special questions as part of a
Table 2 Content of the GANI_MED standardized medical
history
Content Obligatory items* Special items†




Cardiac conditions 7 -
Arterial hypertension 10 6
Coronary artery diseases 36 203
Inflammatory heart diseases - 135
Heart failure - 14
Cardiomyopathy - 28
Valve defects - 113
Cardiac arrhythmia - 208








Gastrointestinal diseases 9 100
Liver/biliary tract diseases 29 80
Pancreatic diseases 14 131
Renal diseases 35 181
Metabolic diseases 42 8
Cancer 226 -
Stroke 36 632
Neurological conditions - 204
Dermatological diseases - 8
Inflammatory joint diseases - 13
Gynecological conditions - 270
Dental conditions - 56
Mental disorders 44 40
Operations and therapies 8 -
Current conditions 124 45
Family history - 16
Health behavior 142 3
Social history 8 12
*Standard in all cohorts †used only in some cohorts.
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tured questions are directly coded in a portable com-
puter. Each patient recruited for GANI_MED is interviewed
as part of the medical history taking. The main areas cov-
ered by the interview are hypertension, cerebrovascular
diseases, cardiac disorders, thrombosis, pulmonary em-
bolism, peripheral vascular diseases, and gastrointes-
tinal, hepatic, biliary, pancreatic as well as kidney diseases.Furthermore the history of metabolic diseases, stroke, can-
cer, mental disorders, surgery, current complaints, and
current therapies as well as the social history and the his-
tory of health behaviors and lifestyle factors are recorded.
In all, the cohort management IT solution for medical his-
tory covers a total of approximately 8000 electronic Case
Report Form (eCRF) variables. The number of variables
applying to a specific patient’s interview depends strongly
on cohort membership and the course of the interview as
questions are dynamically linked with answers given to
previous questions.
Laboratory measures and biosampling
We have defined a specific set of laboratory parameters
that is routinely measured for every patient on the day
he/she is recruited for GANI_MED. These parameters
include blood count, electrolytes, renal function parame-
ters, liver function tests, blood lipids, inflammatory
markers, and urinary markers (Additional file 1: Table
S1). Furthermore, a comprehensive set of biomaterials
including EDTA-plasma (6 ml), serum (5 ml), urine
(6 ml), saliva (Salivette®, FA Sarstedt), as well as buccal
and tongue smears are collected, assayed (in 850 μl cryo
tubes) and stored in an automated biobank (STC12k-ULT
KiWi Store, FA Liconic, Liechtenstein) for future labora-
tory analyses.
Cohort-specific recruitments and examinations
Besides the core examination program, which includes
the computer-assisted basic medical history and a com-
prehensive medication assessment, blood pressure and
anthropometric measurements, a basic dental examin-
ation, and the common laboratory measurements, each
cohort is characterized by additional examination proce-
dures that are detailed below. The clinical characterization
of patients in the different cohorts is summarized in
Table 1.
Heart failure cohort
The research focus of this cohort is on chronic heart
failure (HF). Patients with suspected or known HF due
to systolic (HF with reduced ejection fraction = HFREF)
or diastolic left ventricular dysfunction (HF with pre-
served ejection fraction = HFPEF) are recruited for this
cohort. Within the HFREF cohort a specific focus is on
patients with dilated cardiomyopathy [13]. HFPEF is
considered in concordance with current recommenda-
tions [14]. The cohort specific phenotyping includes
electrocardiography (ECG), transthoracic echocardiog-
raphy and cardiopulmonary exercise testing in all pa-
tients. For selected subgroups additional examinations
are performed such as cardiac MRI, myocardial biopsies
(in patients with dilated cardiomyopathy), assessment
of endothelial function by flow-mediated dilatation as




















Patient Health Questionnaire – PHQ-9 [4] × × × × × × × ×
Screening Questionnaire – SSQ/CID-S [5] × × × × × × × ×
Screening of the “Stralsunder
Lebensereignisliste” – SLE-S*
× × × × × × × ×
Childhood Trauma Screener – CTS [3] × × × × × × × ×
The Aging Males´ Symptom rating
scale – AMS [6]
- - - - × × × -
International Index of Erectile Function
(IEFF) [7]
- - - - × × - -
KDQOL (Kidney Disease Quality of
Life [8])/SF-36 [9]
- - - × - - - -
Health Questionnaire EQ-5D [10] - - - - - - - ×
EPIC-Nutrition-Questionnaire [11] - - - - - - - ×
Minnesota Living With Heart Failure
Questionnaire (MLHFQ) [12]
× - - - - - - -
Health Cost of Heart Failure* × - - - × - - -
Health Cost of Renal Failure* - - - × - - - -
*Available upon request.
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measurement.
A follow-up for this cohort is intended based on fur-
ther projects within the German Center for Cardiovas-
cular Research (DZHK).
Cerebrovascular disease cohort
This cohort enrolls patients with acute ischemic stroke
or transitory ischemic attacks (TIA) [15] who are admit-
ted to the Stroke Unit of the Department of Neurology.
All patients receive standard acute stroke treatment ac-
cording to international guidelines [16,17] and a compre-
hensive diagnostic work-up including computer tomography
(CT) or MRI, CT-angiography and/or ultrasonography of
extracranial and intracranial arteries, echocardiography,
Holter-ECG, and if necessary, laboratory tests for vasculitis
and hypercoagulopathies to identify the underlying cause of
stroke. Stroke subtypes are classified according to TOAST
and ASCO criteria [18,19]. Affected vascular territories, sites
of the infarction, and presence and extent of white matter
lesions are recorded from brain imaging studies. Stroke se-
verity is assessed with the National Institute of Health (NIH)
stroke scale and the degree of disability is scored with the
modified Rankin scale and the Barthel index on admission
and at discharge. Cognitive function is assessed with the
mini-mental state examination (MMSE) [20]. Furthermore,
we record a comprehensive set of data on pre-hospital
stroke management, symptoms at stroke onset, thromboly-
sis or clot retrieving procedures, secondary prevention ther-
apy, in-hospital complications and concomitant disorders, aswell as the presence of migraine according to International
Headache Society criteria.
Periodontal disease cohort
This cohort includes patients with periodontal diseases. Peri-
odontal disease is an inflammatory disease caused by an in-
fection of the supporting tissue around the teeth which may
lead to tooth loss if left untreated. Besides being a major
cause of tooth loss, periodontal disease may be a risk factor
for various systemic conditions and diseases [21,22]. We re-
cruit patients, who have been on maintenance therapy for a
long time, patients who were incompliant with maintenance
and dropped out, and untreated newly admitted patients.
Cohort specific examinations include MRI of the brain,
ultrasonography of the carotid arteries including common
carotid artery intima-media thickness measurement and as-
sessment for atherosclerotic plaques [23]. The comprehen-
sive dental examination comprises an interview with specific
questions about oral hygiene, and standard dental check-
ups, a gingival examination including measurements of
pocket depth and attachment level, bleeding on probing,
dental plaque (on six different sites per tooth). Biosamples
include subgingival plaque, tongue smear, and stimulated
saliva. Information on dental history and the periodontal
treatment is retrieved from the patients’ charts and trans-
ferred into the GANI_MED data bank.
Renal and renovascular disease cohort
This cohort includes patients suffering from various forms
of renal and renovascular disease. About two thirds of the
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disease (ESKD) on dialysis. Patients are recruited in the
dialysis centers of the KfH (Kuratorium für Dialyse und
Nierentransplantation e.V.), a German nonprofit associ-
ation, in Greifswald, Stralsund, and Demmin. About one
third of the cohort with chronic kidney disease (CKD) is
recruited in the division of nephrology (Department of In-
ternal Medicine A). CKD is assessed by estimating glom-
erular filtration rate from serum creatinine levels using
the Modification of Diet in Renal Disease (MDRD) for-
mula [24], and by measuring the albumin-to-creatinine
ratio in spot urine [25]. Cohort specific examinations
include an ultrasonographic examination of the kidneys, a
microscopic urinary sediment analysis, a standard ques-
tionnaire (Kidney Disease Quality of Life – KDQOL [8]/
SF-36 [9]), quantitative determination of the activity of
a defined panel of proteases in the blood plasma, and
the isolation of RNA and exosomes from urine. It
should be noted that about 20% of the patients re-
cruited by other GANI_MED cohorts exhibit CKD as a
comorbidity (defined by an estimated glomerular filtra-
tion below 60 ml/min/1.73 m2).
Metabolic syndrome risk cohort
Subjects that are on an increased risk for or actually suffer
from metabolic syndrome are eligible for this cohort. Meta-
bolic syndrome is defined as fulfilling three or more of the
following five criteria: (1) Abdominal obesity: waist circum-
ference ≥94 cm or ≥80 cm for men and women, respect-
ively (2) elevated blood pressure: ≥130/85 mmHg or
self-reported antihypertensive medication; (3) elevated
non-fasting glucose: ≥8.0 mmol/l or diabetic medication
(ATC code A10); (4) elevated triglycerides: ≥2.3 mmol/l or
lipid-modifying medication (ATC code C10AB or C10AD);
(5) and reduced high-density lipoprotein (HDL) choles-
terol: <1.03 mmol/l or <1.29 mmol/l for men and women,
respectively. This definition has been proposed by the Na-
tional Cholesterol Education Program/Adult Treatment
Panel III (NCEP/ATP III) [26], and the International Dia-
betes Federation [27] updated with minor modifications by
the American Heart Association and the National Heart,
Lung, and Blood Institute [28] using non-fasting blood
samples [29,30].
All patients fulfilling the criteria for metabolic syn-
drome without meeting the diagnosis of diabetes melli-
tus receive an oral glucose tolerance test.
In order to assess possible hormonal disturbances re-
lated to distinct comorbid conditions associated with the
metabolic syndrome, this cohort consists of three sub-
cohorts:
 Patients with the primary diagnosis of mental
disorders are recruited from the day clinic of the
Department of Psychiatry and Psychotherapy. Allpatients of the day clinic are invited to take part in
the GANI_MED project. The main diagnoses of
these patients are depressive disorders (90%), anxiety
and somatoform disorders, trauma-related disorders
and personality disorders.
 Women with polycystic ovary syndrome (PCOS)
are recruited at the Department of Obstetrics and
Gynaecology. PCOS is a highly prevalent
heterogeneous disease affecting 1 in 5 women in
reproductive age. PCOS is characterized by clinical
or biochemical androgen excess and/or
anovulation, and polycystic ovaries on ultrasound.
PCOS increases the risk of insulin resistance, type
2 diabetes mellitus, visceral obesity, cardiovascular
disease, infertility, and depression. The etiology of
PCOS remains unclear and the highly individual
phenotype makes diagnosis difficult. It seems that
PCOS is caused by a combination of
environmental and genetic factors. New and
individualized strategies are needed for an early
diagnosis and age adjusted treatment. A
comprehensive characterization of clinical
phenotypes, clinical risk profiles as well as the
identification of biological correlates from genome,
proteome, transcriptome, and metabolome data is
performed.
 Patients with the metabolic syndrome and prevalent
cardiovascular diseases (e.g., coronary artery disease,
myocardial infarction, hypertensive heart disease)
and at least three metabolic syndrome criteria are
recruited from the Department of Internal Medicine
B/Cardiology. For specific phenotyping of selected
subjects of this cohort, methods that are also
applied in the cardiovascular cohort are being used
(ECG, transthoracic echocardiography,
cardiopulmonary exercise testing, assessment of
endothelial function, pulse wave analysis, 24-h blood
pressure measurement).
Fatty liver disease cohort
This cohort includes patients with non-alcoholic fatty liver
disease (NAFLD). Screening of patients is performed by
transabdominal ultrasound. In case of a hyperechogenic
pattern of the liver parenchyma in comparison to the kid-
ney patients are recruited for the study. The diagnosis of
NAFLD is based on a positive ultrasound examination in
conjunction with a NAFLD score of < −1.455 to <0.675
(low-cut-off: estimated sensitivity 90%, specificity 60%)
[31,32] or an APRI score of >0.5 [33]. Patients with at least
one of the following conditions are excluded: Liver cirrho-
sis, alcohol abuse or consumption >30 g alcohol per
day, pulmonary hypertension, dilated cardiomyopathy
with ejection fraction < 30%, autoimmune hepatitis, viral
hepatitis, Wilson disease (hepatolenticular degeneration),
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malignoma of the liver, primary biliary cirrhosis or pri-
mary sclerosing cholangitis. A cohort specific interview
has been developed addressing relevant information for
NAFLD disease. Cohort specific examinations include
ultrasonography and real time tissue elastography of
the liver using a Preirus device (Hitachi, Tokyo, Japan).
In a fraction of patients liver biopsy is obtained, pro-
vided that it is clinically indicated. The liver elasticity
score is done on 10 images with compression values of
3–4 on a scale elastography of the liver. Bioelectrical
body impedance analysis is performed using Nutri-
guard M (Data Input GmbH, Darmstadt, Germany). R
(resistance) and Xc (reactance) are measured applying
electric currents of 800 mA at 50 kHz. Source and sen-
sor electrodes are placed on the dorsum of hand and
foot of the dominant body side. A quantitative chem-
ical shift-encoded MRI to quantify hepatic steatosis is
performed [34]. Further, a dietary questionnaire and a
validated score to assess physical activity [11] are ad-
ministered as well as the EQ5D [10] for the assessment
of Quality of Life.
A cohort of patients with acute and chronic pancrea-
titis is recruited in parallel for comparison of pheno-
typic, genetic and metabolic characteristics as well as
biomarkers.
Cohort of adverse medication effects
This cohort includes all patients who are admitted to
the Departments of Internal Medicine due to severe ad-
verse drug reactions (ADR). All non-elective hospital admis-
sions are screened for ADR by a clinical pharmacologist. In
patients with suspected ADR, a detailed history (demo-
graphical patient data, admission diagnosis, comorbidities,
risk factors, drugs taken prior to onset of reaction) is ob-
tained and results of clinical and laboratory tests as well as
ADR description (e.g., severity, course, outcome) are gath-
ered. Patients receiving cancer chemotherapy are excluded.
Outcomes of ADRs are classified according to Inter-
national Conference of Harmonization (ICH) guidelines.
The assessment of ADR severity is based on the adverse
drug reaction reporting system described by Hartwig
et al. [35]. Classification of ADR types is performed ac-
cording to Edwards & Aronson [36]. A standardized
causality assessment of each drug taken before the hos-
pital admission is made using the Begaud algorithm [37].
Preventability of ADRs is assessed by standardized cri-
teria (e.g., non-adherence, dose-related problems, rele-
vant drug-drug-interactions). All ADRs are reviewed in a
quality assurance and clinical plausibility check by a sec-
ond clinical pharmacologist.
Incidences of ADRs will be estimated by the number of
events per 1000 treated patients per year using prescrip-
tion data provided by health insurances. Blood samples forgenotyping are collected from all patients with ADR in
order to identify genetic risk factors using modern tech-
nologies of pharmacogenomic approaches.
Recently launched cohorts:Cohort of pulmonary diseases
The aim of this cohort is a thorough characterization of
the individual cardiovascular risk factor profile and the
co-morbidities in patients with chronic obstructive pul-
monary disease (COPD). This cohort is set up to clarify
the association of various co-morbidities with cardiopul-
monary capacity, quality of life, and ultimately the mor-
tality risk of patients. In-patients with COPD (defined by
obstructive ventilation problems and clinical symptoms)
are included in this cohort in accordance with current
guidelines [38]. We aim at recruiting 300 patients. An
extensive medical history taking, clinical examination,
somatometric measures, blood pressure, assessment of
oral status (number of teeth), ECG, and transthoracic
echocardiography are performed in each patient. The co-
hort specific phenotyping includes a six-minute walk test
(6-MWT) [39], lung function analysis, blood gas ana-
lysis, and polysomnography. In a selected subgroup, add-
itional measurements will be performed including MRI
scanning of thorax, heart, and hamstring muscle.
Examinations are complemented by specific question-
naires regarding sleep-associated symptoms (Berlin Ques-
tionnaire [40], Epworth Sleepiness Scale [41], Index of the
Severity of Insomnia (ISI) [42], Pittsburgh Sleep Quality
Index (PSQI) [43], and a COPD-specific Assessment Test
(CAT) [44]). Hence the generation of established prognos-
tic indices (Bode-Index [45], ADO-Index [46]) and recent
COPD graduations [47] is possible. All COPD patients are
offered participation in the long-term monitoring study
COSYCONET that will eventually include about 3,000
COPD.Cohort of sepsis
Sepsis and septic shock still contribute significantly to
in-hospital mortality, in particular in intensive care
units, despite major progress in hygiene and antibiotic
treatment [48]. To date, all major trials trying to repeat
promising experimental approaches from the bench
and animal studies in septic patients have failed. It re-
mains unclear which combination of patient characteris-
tics may determine the clinical course of the condition,
and therefore the survival of the patients [49]. Patients are
enrolled in the cohort, based on established sepsis cri-
teria. All patients are followed up for three consecutive
time points. The major aim of this cohort is to identify
clinical and OMICS-markers that allow for prediction
of the sepsis course and may guide individual treat-
ment decisions.
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Individualized Medicine requires complex platforms to
acquire and manage data sets for evidence-based research,
including data transformation, normalization, and long
term storage. A high degree of automation is essential to
efficiently acquire, integrate and apply Use & Access rules
to data from a variety of sources, including electronic Case
Report Forms (eCRF), a patient’s health record, diagnostic
devices such as MRI, sonography, and ECG, or sources for
secondary data like a population register, health insurance
or a patient’s family doctor [50]. Compliance with public
and local regulations of data privacy as well as information
security has to be ensured. Scalability and high availability
of at least those tools that are used to record data is an-
other key aspect to consider. Applicability of the Medical
Device Directive (MDD) of the EU, together with country-
specific regulations, must be carefully considered when
designing and operating such platforms and tools. The in-
formed consent is a basic requirement for the scientific
use of patient data. GANI_MED adopts a modular con-
sent design that allows patients to agree or disagree to
particular modules in an opt-in model (e.g., use of data,
biomaterials, information about incidental findings, con-
tact in the future). An independent Trusted Third Party as
institutional as well as technical instrument is imple-
mented to centrally manage the informed consents of
all GANI_MED participants. Furthermore, the Trusted
Third Party ensures unique and platform-wide identifi-
cation of persons, independent from data source and local
identifiers. Another unique identifier (Master Person
Index) is used as a link between all source-specific
identifiers and identities. A probabilistic approach al-
lows tolerating minor spelling mistakes or missing in-
formation; ambiguous matches are resolved manually
at a later point of time while data can be recorded con-
tinuously. A conservative approach is taken in case ofFigure 1 Architecture and basic elements of the GANI_MED researchan ambiguous match: two identifiers are used, which
can be combined once both identities have been ap-
proved as belonging to a single person. Furthermore
the Trusted Third Party generates and manages all
pseudonyms used throughout the platform. The tools
used in GANI_MED can operate on almost arbitrary al-
phabets (numeric, characters, special characters, mixes).
Parameters can be adjusted to optimize for error correc-
tion or error recognition. Use & Access of data is managed
through a transfer unit. When transferring data to a re-
search project, all pseudonyms are made project-specific
pseudonyms to prevent aggregation of larger data sets
across a number of projects. Figure 1 shows the high-level
architecture of the GANI_MED research IT-platform.
Cohort management is done using Java-based offline-
capable eCRF software on mobile clients, so-called Mo-
bile Clinical Assistants [51]. These are used to record
patients’ personal data, document the informed consent,
and generate a cohort-specific number of dynamic eCRF-
based data, including lab order IDs and similar links to ex-
ternal sources. All data are synchronized with a server
application which functions as one of the data sources
(left hand side of Figure 1). Currently, the cohort man-
agement is used for nine GANI_MED cohorts, imple-
menting 225 electronic forms, more than 8,000 variables
and 200,000 data sets. The Extraction Layer of the plat-
form accounts for separating personal (i.e., identifying)
data from medical data and performs source-specific
transformations into a platform-internal unified data
format for further processing. Presently (March 3, 2014),
the platform operates on 18 million data points for 3,535
persons participating in GANI_MED. The three functional
blocks of the Trusted Third Party have successfully been
re-used and adapted for other projects such as the
German Center for Cardiovascular Research (DZHK) or
The National Cohort in Germany, a large representativeIT-platform.
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subjects in 2014.
Storage facility for biosamples
An automated biobank (STC12k-ULT KiWi Store, FA
Liconic, Liechtenstein) was installed to store and handle
up to 500,000 cryo tubes of 1 ml volume at a constant
temperature of -80°C. Nineteen cryo tubes with biomate-
rials including serum (N= 5), EDTA-plasma (N = 5), urine
(N = 5), saliva (N = 2), and DNA (N = 2) are processed and
stored for each patient.
Deep phenotyping of patients with genomics and
functional genomics approaches
Deep phenotyping of patients with genomics and func-
tional genomics approaches provides molecular informa-
tion at unprecedented detail that will allow much more
in-depth description of the (patho)physiological status of
a patient. The OMICs data generated at different levels
(genomics, transcriptomics, proteomics, and metabolo-
mics) will likely allow for better descriptions of health
and disease states [52]. Within GANI_MED, standard-
ized workflows for the OMICs characterization of bio-
samples will be developed. Currently, genomic variants
are analyzed for 1,800 patients with the aid of the Human-
CoreExome + v1.1-Psych Array. For a subset of 1,200 pa-
tients, whole blood expression data are generated using
Illumina’s HT-12 bead chips. These data will be comple-
mented with proteomics and metabolomics data using
established workflows.
Metabolomics provide comprehensive snapshots of the
metabolome of body fluids such as plasma, urine or sal-
iva. Within GANI_MED, high-throughput metabolomics
analyses mainly based on 1H nuclear magnetic reson-
ance (NMR) spectroscopy, a non-destructive analysis
with minimal preparation requirements, are performed.
NMR spectroscopy provides robust and reproducible
measurements. Mass spectrometry (MS) with high ana-
lytical sensitivity will be used for additional detailed
studies.
Integrated analyses of these data for associations with
clinical and subclinical phenotypes will be performed by
the bioinformatics groups of the GANI_MED consortium.
Economic aspects of Individualized Medicine
The health economic analysis contributes to the com-
prehensive assessment of advantages and disadvantages
of Individualized Medicine by comparing costs of in-
novative diagnostics with their effectiveness. One focus
lies on the performance of an economic evaluation of
the predictive value of genetic and non-genetic bio-
markers to forecast health care costs. The analysis which
is based on SHIP data, correlates genetic and non-genetic
biomarkers with the health seeking behavior and/or healthcare expenditure [53]. For instance, we demonstrated that
rs738409 (GG) in PNPLA3 is a significant predictor of
hospital admissions for gallstone complaints. Secondly, we
perform cost analyses of severe drug-related side effects as
they are a major cause of hospital admissions and cause a
large fraction of the global health care expenditure. Thus,
it is crucial to understand the costs and benefits of specific
treatment options or diagnostic tests such as genetic test-
ing. We could show that the immense costs caused by
intestinal bleeding as a side effect of phenprocoumon
therapy are so high that a specific genetic test for every
patient taking this drug would be cost-effective [54].
Thirdly, economic analyses evaluate the cost-effectiveness
of specific therapeutic interventions of Individualized
Medicine [55].
Ethical research
One general strategy in GANI_MED is the recruitment
of patients during ongoing clinical routine care. This
means that hospitalized patients are being asked to make
their clinical data and biomaterial available for scientific
research. Thus, one major challenge for the ethical work-
ing group was to develop an appropriate information con-
cept to enable patients to give their informed consent.
This informed consent procedure covers the multilevel as-
sessment of personal, clinical and biological data as well
as the storage and use of data and the biobanking. All in-
formed consent procedures are carried out according to
standards of law, data protection, and research ethics. This
includes the preparation of the information and consent
forms, an ongoing training for the GANI_MED staff as
well as the design and implementation of workflows and
standard operation procedures regarding all ethically sen-
sitive processes in GANI_MED [56,57].
Some GANI_MED cohorts also include non-treatment
related study examinations. Ethical challenges emerge, if
incidental findings, that might be relevant for the health
of the participants, occur in these cases. Their manage-
ment does not follow clinical routine care. Especially
when the participant does not suffer from any symptoms
of illness researchers need to weight potential harm
against potential benefit of disclosure of medical findings
for the participant. The benefit might be the early detec-
tion and treatment of pathological states whereas invasive
diagnostic procedures as well as psychological distress as-
sociated with the disclosure of incidental findings repre-
sent relevant negative consequences.
The non-clinical use of imaging methods like the whole
body MRI or genome-wide data represents an ethical and
psychological challenge in case of incidental findings.
To address this issue, one of our ethical research pro-
jects specifically focuses on the disclosure of incidental
findings. The project applies methods from empirical so-
cial research to examine how the disclosure of incidental
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search projects. This is done within the framework of
the population-based SHIP study [2] at the University
Medicine Greifswald with a special focus on the whole
body MRI. The view of the participants is inferred from
their answers to questionnaires and interviews with SHIP
participants who were informed about their incidental
MRI findings [58-60].
Reference groups for case–control comparisons
The University Medicine Greifswald has a long tradition
in community-based research. SHIP is a large prospect-
ive cohort study that was implemented in 1997 (SHIP-0)
to investigate a broad spectrum of health-related param-
eters in West Pomerania, a rural area in the north-east
of Germany with a relatively short life expectancy as
compared to that in the average German population [2].
Over the past 15 years, the population-based study SHIP
has evolved as cohort study with one of the most com-
prehensive phenotype assessments worldwide covering
the follow-up waves SHIP-1, SHIP-LEGEND and SHIP-
2. From 2008 to 2012 a new, independent sample called
SHIP-TREND was recruited (n = 4420). Both representa-
tive samples from the general population serve as ref-
erence sample for case–control comparisons with the
GANI_MED patient cohorts. The university hospital
Greifswald is the only major hospital in the area. The
SHIP sample was derived from the same geographic
area, ensuring that patient cohorts and control groups
originate from the same population.
Access to the GANI_MED data
External collaborations are welcome. For the coordination
of research projects based on the GANI_MED data, a re-
quest and transfer process has been established that
largely follows the procedure established in SHIP. A web-
based request form will be available soon. Meanwhile in-
terested researchers may download a form at the data
transfer unit (http://www.community-medicine.de) and send
the completed document to grabeh@uni-greifswald.de.
Together with collaborators at the University Medicine
Greifswald we will select the necessary variables and
complete the application. Once the application has been ap-
proved, a contract is concluded between the external appli-
cant and the Research Network of Community Medicine.
Discussion
We will apply hypothesis-generating and hypothesis-
testing approaches with additional replication and valid-
ation steps. Those strategies include the testing of
associations in SHIP-0 and the replication of the findings
in SHIP-TREND. In a translational step, associations will
be transferred to the clinical samples of GANI_MED to
check for their validity in severely ill patients. On theother hand, associations primarily identified in clinical
setting can be tested for their relevance in the general
population. Identified or suspected biomarkers can be
tested for their predictive value for incidental diseases in
the longitudinal waves of SHIP. Clinical samples from
GANI_MED can be stratified based on clinical and bio-
logical markers and investigated for differential outcomes,
courses, and treatment responses. Biological mechanisms
will be addressed by biological systems approaches and
other experimental approaches such as cell culture and
animal studies, which are performed in collaboration with
our local, national or international collaborators.
Highlights
As data collection and OMICS analyses in GANI_MED are
still ongoing, research is focusing on the analyses of SHIP
and laboratory data to generate new hypotheses for transla-
tional research. Research in the field of hormones like tes-
tosterone, prolactin and IGF-1 as individual biomarkers
and putative predictors of clinical outcomes (e.g., hyperten-
sion, depression, inflammation) has been especially suc-
cessful [61-66]. Novel biomarkers like angiopoietin-2,
Tie-2 [67], homoarginine and asymmetric dimethylar-
ginine (ADMA) [68] are under investigation. Metabolites
have been analyzed by NMR and mass spectroscopy and
are currently tested for their association and predictive
properties in various diseases [69]. Strong associations be-
tween genetic variations and metabolites have been dis-
covered [70]. Myocardial gene expression profiles have
been used to successfully predict the treatment response
to immunoadsorption therapy in patients with dilated
cardiomyopathy [71]. The important interface between
oral and systemic health is increasingly addressed in
GANI_MED [72], especially the inflammatory effects
of periodontitis [73]. Growth factor receptor-mediated
signaling is meanwhile recognized as a complex signal-
ing network. The interactome of the epidermal growth
factor receptor (EGFR) was identified and quantified.
The newly developed Cytoscape plugin ModuleGraph
facilitated the extension and functional investigation of
this network [74]. A short 5-item questionnaire for
routine clinical assessment of childhood abuse and
neglect has been developed and validated [3,75]. Thus,
the effects of gene-environment interactions in somat-
ically burdened patients can be investigated [76,77].
A standardized protocol for fat quantification in fatty
liver disease on liver MRI has been developed and vali-
dated within this cohort [34,78,79].
Conclusions
As new levels of biological markers (e.g. genomics, tran-
scriptomics, metabolomics, proteomics) are becoming in-
creasingly available at a decreasing level of costs, medical
research is obliged to explore the new insights derived
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tical use in medicine. We need to explore the new bio-
logical markers to discover, validate and implement novel
biomarkers that allow for better and individualized diag-
nostics and therapies. We have managed to implement an
extensive infrastructure for the collection of standardized
clinical data, laboratory analyses, technical examinations
and biobanking for routine patients in our university hos-
pital. A comprehensive informed consent procedure was
established that enables re-contacting and follow-up of
the patients. This effort should be pursued jointly with
academic partners as well as health care and biotechnical
companies. In the near future, we plan to build up an IT-
based network with local general practitioners and special-
ists for the communication of relevant health information.
For the use and interpretation of novel biomarkers local
general practitioners and specialists will need some guid-
ance and support which we will provide in a collaborative
way.
Additional file
Additional file 1: Table S1. Laboratory parameter in GANI_MED.
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